Amwell (AMWL) Q1 2024: Converge Platform Adoption Hits 68%, Setting Up 30% 2025 Growth Inflection
Converge, Amwell’s next-gen digital care platform, now powers nearly 70% of visits, marking a pivotal shift in business mix and operational scale. Q1 revealed accelerated client migrations, deeper government sector traction, and a reset cost structure, all pointing toward a high-margin, software-driven model. With the DHA deployment and subscription mix ramping, Amwell’s 2025 and 2026 path to profitability is now grounded in visible, contracted backlog and margin expansion.
Summary
- Platform Migration Drives Mix Shift: Converge adoption accelerates, underpinning margin and revenue quality improvements.
- Government Sector Expansion: DHA rollout cements Amwell’s position in large, complex digital health deployments.
- Cost Structure Reset: Organizational transformation and R&D normalization position Amwell for operating leverage as growth returns.
Business Overview
Amwell is a digital health enablement company providing telehealth and hybrid care solutions to payers, providers, and government entities. Revenue is generated from three main streams: subscription software (recurring SaaS for digital care delivery), AMG visit revenue (fee-for-service virtual care), and services/care points (deployment and professional services). The Converge platform, Amwell’s core product, integrates digital, automated, and in-person care, targeting large-scale healthcare systems and payers transitioning to hybrid care models.
Performance Analysis
Q1 marked a transition quarter for Amwell, with total revenue declining year-over-year primarily due to legacy platform attrition and temporary visit disruptions. Subscription software revenue, now the strategic focus, reached its low point for the year but is set to grow sequentially as contracted go-lives ramp through 2024. Visit volumes were pressured by a one-time industry security breach (Change Healthcare) and the largest client migration in Amwell’s history, both now resolved.
Converge adoption surged, powering over 68% of total visits, up from 54% in Q4, and client feedback remains strong with >90% satisfaction. Gross margin compressed temporarily due to migration costs and lower subscription mix, but management reiterated full-year and long-term guidance for margin expansion as software mix rises. The balance sheet remains robust, with $309 million in cash and investments, supporting the company’s multi-year transformation plan.
- Subscription Revenue Inflection: Q1 was the trough, with sequential growth expected as backlog converts through 2024.
- Visit Volume Impacted by External Disruption: Change Healthcare breach and migration timing drove a temporary dip, with underlying demand intact.
- Cost Actions Take Hold: R&D and SG&A reductions are tracking to plan, unlocking >$15 million in annual savings and setting up 2025 operating leverage.
Amwell’s revenue mix is now tilted toward high-value, multi-year contracts, with 90% of 2025 growth underpinned by contracted backlog, giving rare visibility for a digital health platform at scale.
Executive Commentary
"It is now clear that the need for digital care enablement is significant. It is also clear that Converge is performing well and powers sophisticated solutions across diversified clients on a large scale. And finally, it is evident that new large customers are recognizing the value of our platform as reflected by the size and revenue mix of our recent wins."
Dr. Ido Schoenberg, Chairman & CEO
"We expect revenue in 2025 to be in the range of $335 to $350 million, representing growth of circa 30% compared to 2024, primarily driven by go-lives of contracted software backlog, including our planned enterprise-wide DHA deployments. We further expect an approximate 70% improvement in our adjusted EBITDA."
Bob Shepardson, CFO
Strategic Positioning
1. Converge Platform Scale and Differentiation
Converge, Amwell’s unified digital care platform, is now the backbone for the majority of client visits, with migration of major payers (e.g., Elevance, Highmark) completed. This shift enables higher-margin, recurring SaaS revenue and positions Amwell as a technology partner for large, complex healthcare systems. Client satisfaction and NPS remain high, supporting retention and expansion.
2. Government Sector as Growth Catalyst
The Defense Health Agency (DHA) deployment marks Amwell’s entrance into the government vertical, with a $180 million budgeted contract as part of a $4 billion task order. The rollout is on schedule, with behavioral health live and full enterprise deployment set for Q4. This not only expands Amwell’s TAM (total addressable market) but also provides a referenceable proof point for cybersecurity, scalability, and compliance capabilities.
3. Cost Structure Realignment and Operating Leverage
Amwell has executed a company-wide transformation, reducing R&D and SG&A, upskilling sales, and consolidating roles to focus on high-margin software sales. These changes unlock $15 million in annual savings and align incentives with software subscription growth, setting up for operating leverage as revenue returns to growth in 2025.
4. Enterprise Sales and Client Expansion Model
Sales motions have shifted to an enterprise, ROI-driven approach with integrated teams managing both new and existing clients. Renewals (e.g., Intermountain, Cleveland Clinic) are adding advanced capabilities such as virtual primary care, automated care programs, and collaborative behavioral health, driving same-store growth and higher revenue per client.
5. Backlog Visibility and Margin Trajectory
90%+ of 2025 growth is locked in via contracted backlog, primarily from software go-lives and the DHA rollout. Gross margin is set to expand from the high 30% range in 2024 to over 50% in 2025, as subscription software becomes the dominant revenue driver.
Key Considerations
Q1 was a foundational quarter, with operational execution and strategic repositioning setting the stage for Amwell’s next growth phase. Investors should weigh the following:
Key Considerations:
- Converge Penetration Accelerates: With nearly 70% of visits on the new platform, Amwell is now positioned to capture higher-margin, recurring revenue at scale.
- Government Deployments Open New Markets: DHA rollout validates Amwell’s platform for large, security-conscious clients and creates a reference for further public sector wins.
- Cost Discipline and Efficiency Gains: Organizational restructuring and R&D normalization provide a credible path to profitability, even as top-line recovers.
- Revenue Mix Transformation: Subscription backlog and renewals drive visibility, while legacy revenue headwinds are receding as migrations complete.
- Competitive Landscape Rationalizes: Exits by tech-driven digital health players (Optum, Walmart) reinforce the need for deep integration and trusted provider networks, favoring Amwell’s partnership model.
Risks
Execution risk remains around the DHA enterprise deployment, where delays or performance issues could impact both revenue timing and reputation. Healthcare provider and payer budgets remain pressured, and macro uncertainty could weigh on new bookings. Competition from entrenched EHR vendors and point solutions persists, though recent market exits suggest barriers to scale are rising. Visibility is high for 2025, but 2026 profitability depends on continued margin expansion and cost discipline.
Forward Outlook
For Q2 and Q3 2024, Amwell guided to:
- Incremental sequential growth in subscription revenue as contracted go-lives ramp.
- Services and care points revenue to rise, with two-thirds of annual total recognized in the second half, driven by DHA milestones.
For full-year 2024, management reiterated guidance:
- Total revenue of $259 to $269 million, with subscription revenue flat year-over-year.
- Adjusted EBITDA loss of $160 to $155 million, with cost reductions tracking to plan.
2025 guidance remains for 30% revenue growth and gross margin expansion to over 50%, with adjusted EBITDA loss narrowing by 70%. Management cited high conviction in backlog conversion and cost structure improvements.
- Subscription mix and DHA go-lives are the primary drivers of growth and margin gains.
- Profitability targeted for 2026, with $150 million in projected cash at breakeven.
Takeaways
Amwell’s Q1 results confirm a successful pivot to a high-margin, software-centric model with the Converge platform now at operational scale. Government sector wins and a reset cost base provide rare visibility into 2025 growth and profitability milestones.
- Converge Adoption Is the Core Growth Engine: Platform migration is driving both revenue quality and client stickiness, with proven scalability in payer and government verticals.
- Cost Structure Transformation Underpins Margin Story: R&D and SG&A reductions, combined with a focused sales approach, are unlocking operating leverage as revenue growth resumes.
- 2025 and Beyond Hinge on Backlog Execution: Investors should track DHA deployment milestones, subscription software ramp, and the sustainability of client expansion and renewals as key forward indicators.
Conclusion
Amwell’s Q1 marked an inflection point: operational disruptions are behind, Converge is scaling, and the DHA contract anchors the growth trajectory. With cost discipline and high contract visibility, Amwell is positioned to deliver on its profitability roadmap and emerge as a leading digital health platform partner.
Industry Read-Through
Amwell’s quarter signals a maturing digital health landscape, where platform integration, trusted provider networks, and government-grade security are prerequisites for scale. Exits by retail and tech-first players (Optum, Walmart) highlight the complexity of hybrid care delivery and the rising bar for digital enablement. Health systems and payers are demanding proven ROI and seamless integration, favoring enterprise platforms like Converge. For the industry, the shift to software-driven, hybrid care is accelerating, but only those with deep client relationships and operational credibility are positioned to capture durable share as digital health moves from innovation to infrastructure.